Discover scPharmaceuticals' Q4 2024 achievements, including FUROSCIX's CKD approval, Medicare redesign insights, and strategies for 2025 growth.

Pharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S ...

Pharmaceuticals Inc (SCPH) reports a 167% revenue growth and strategic advancements, despite facing increased expenses and ...

Good afternoon, and welcome to scPharmaceuticals fourth-quarter and full-year 2024 earnings conference call. (Operator Instructions) As a reminder, today's conference is being recorded. I would now ...

Maxim analyst Naz Rahman lowered the firm’s price target on scPharmaceuticals (SCPH) to $12 from $20 but keeps a Buy rating on the shares after ...

scPharmaceuticals reported Q4 2024 revenue of $12.2 million, FDA approved FUROSCIX for chronic kidney disease, and a net loss of $18.8 million. FUROSCIX is indicated for treating edema in patients ...

Reports Q4 revenue $12.2M, consensus $12.18M..Reports Net FUROSCIX revenue of $12.2m and $36.3mfor the fourth quarter and full year 2024, ...

U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease ...

U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease ...